BC Extra | Nov 15, 2019
Company News

Sarepta partners with StrideBio to enable viral gene therapy re-dosing

To enable repeat dosing of adeno-associated virus gene therapies, Sarepta is partnering with StrideBio to use the latter’s capsid technology in up to eight CNS and neuromuscular programs. The immunogenicity of viral antigens limits the...
BC Extra | Oct 3, 2019
Politics & Policy

Experimental GBM vaccine available under U.S. right-to-try program

ERC is making its experimental glioblastoma multiforme vaccine Gliovac available to patients under a program based on the federal right-to-try law. The company is the first to develop an experimental therapy program to treat patients...
BC Extra | Jul 10, 2019
Clinical News

Michael Becker: a voice with purpose

Michael Becker, biotech industry veteran, expert cancer patient, and unstinting advocate for HPV vaccination, died July 9 from HPV-positive oropharyngeal cancer. He was 50. In the two years since I met Michael, he pursued his...
BC Week In Review | Jan 11, 2019
Clinical News

Patient receives glioblastoma vaccine under right to try

ERC-USA and the University of California Irvine announced that a patient with recurrent glioblastoma multiforme is receiving therapeutic vaccine ERC1671 under California's right-to-try (RTT) law. ERC1671 is in a U.S. Phase II trial as part...
BC Extra | Jan 9, 2019
Clinical News

Patient receives glioblastoma vaccine under right to try

ERC-USA and the University of California Irvine announced that a patient with recurrent glioblastoma multiforme is receiving therapeutic vaccine ERC1671 under California's right-to-try (RTT) law. ERC1671 is in a U.S. Phase II trial as part...
BC Extra | Jun 21, 2018
Company News

Sarepta says no to right to try for its DMD therapies

Following data from a small trial of a Duchenne muscular dystrophy gene therapy, Sarepta Therapeutics Inc. (NASDAQ:SRPT) told BioCentury that it will not offer pre-approval access under right-to-try legislation or FDA’s expanded access program for...
BC Extra | Jun 7, 2018
Company News

BrainStorm considering right to try for ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury. He also discussed the company’s plans...
BC Extra | May 17, 2018
Politics & Policy

House to vote on Senate's right-to-try bill

House Majority Leader Kevin McCarthy (R-Calif.) said the House of Representatives will vote next week on a right-to-try bill ( S. 204 ) passed by the Senate last August that seeks to authorize using investigational treatments for...
BC Week In Review | Mar 23, 2018
Company News

NORD grades states on health policy

The National Organization for Rare Disorders said in its annual report card that many state laws were not sufficient to reduce the burden of rare disease on Americans. The report, which grades the strength of...
BC Extra | Mar 20, 2018
Politics & Policy

NORD says states come up short on health policy

The National Organization for Rare Disorders said in its annual report card that many state laws were not sufficient to reduce the burden of rare disease on Americans. The report , which grades the strength of...
Items per page:
1 - 10 of 48